Subconjunctival and intracorneal bevacizumab injection for corneal neovascularization in lipid keratopathy.
OBJECTIVE
The purpose of this study was to evaluate the efficacy and safety of subconjunctival and corneal intrastromal bevacizumab injections on corneal neovascularization in patients with lipid keratopathy.


METHODS
Three eyes of 3 patients with lipid keratopathy accompanied by corneal neovascularization received at least 2 subconjunctival and corneal intrastromal injections of bevacizumab (1.25 mg/0.05 mL, respectively) at 1-month intervals. Ophthalmic examinations, including visual acuity, tonometry, slit lamp biomicroscopy, and corneal topography, were performed before injection and every month thereafter.


RESULTS
All patients had marked regression of corneal neovascularization. Reduction in lipid deposition was noted in one patient. There were no adverse ocular or systemic events, except for a small intracorneal hemorrhage noted in one patient, which quickly and spontaneously cleared.


CONCLUSIONS
Subconjunctival and intracorneal bevacizumab is a well-tolerated and effective method for obliterating corneal neovascularization in lipid keratopathy.
Oh
Joo Youn
JY
Department of Ophthalmology, Seoul National University College of Medicine, Seoul 110-744, Korea.
Kim
Mee Kum
MK
Wee
Won Ryang
WR
D000328:Adult; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D003228:Conjunctiva / Q000187:drug effects*; D016510:Corneal Neovascularization / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D003319:Corneal Stroma / Q000187:drug effects*; D019781:Corneal Topography; D005260:Female; D006801:Humans; D007267:Injections; D007429:Intraocular Pressure / Q000502:physiology; D052439:Lipid Metabolism Disorders / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D010743:Phospholipids / Q000378:metabolism; D014065:Tonometry, Ocular; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000502:physiology
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D010743:Phospholipids; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab